Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.

NCT04931654 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04931654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04931654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 28, 2021
Completion date
August 12, 2026
Enrollment
136 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, gastric cancer, gastroesophageal junction cancer